Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 17, 2024JACC Heart FailureOpen Access

Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction

View Full Paper
Ask AI
Bookmark
Share

Authors

SSSenthil SelvarajSPShachi PatelASAndrew J. Sauer

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Selvaraj et al. (2024) studied this question.

synapsesocial.com/papers/68e6eabeb6db643587665dddhttps://doi.org/10.1016/j.jchf.2024.02.018
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial2021 · 625 citations
  2. 2Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes2016 · 733 citations
  3. 3Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction2015 · 222 citations
  4. 4Skeletal Muscle Mitochondrial Respiration and Exercise Intolerance in Patients With Heart Failure With Preserved Ejection Fraction2023 · 110 citations
  5. 5Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF2022 · 104 citations